Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor ev...

Full description

Bibliographic Details
Main Authors: Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger, Marcus Krüger
Format: Article
Language:English
Published: MDPI AG 2017-08-01
Series:International Journal of Molecular Sciences
Subjects:
metastatic renal cell carcinoma
lenvatinib
everolimus
hypertension
multikinase inhibitors
mTOR inhibitor
vascular endothelial growth factor
Online Access:https://www.mdpi.com/1422-0067/18/8/1736

Internet

https://www.mdpi.com/1422-0067/18/8/1736

Similar Items